πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Kodiak Sciences Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. logo
Market Cap: Medium
Employees: Low

KVD001, sebetralstat, KVD824, Factor XIIa

Kal Vista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on discovering, developing, and commercializing small molecule protease inhibitors for diseases with unmet needs, including hereditary angioedema and diabetic macular edema.

Tags: Clinical Trials, Diabetic Macular Edema, Hereditary Angioedema, Pharmaceuticals, Protease Inhibitors

Symbol: KALV

Recent Price: $8.39

Industry: Biotechnology

CEO: Mr. Benjamin L. Palleiko

Sector: Healthcare

Employees: 150

Address: 55 Cambridge Parkway, Cambridge, MA 02142

Phone: 857 999 0075

Leadership

  • Albert Cha, Member of Board of Directors
  • William (Bill) Fairey, Member of Board of Directors
  • Benjamin L. Palleiko, Chief Executive Officer and Director
  • Brian J. G. Pereira, Member of Board of Directors
  • Nancy Stuart, Member of Board of Directors
  • Pat Treanor, Member of Board of Directors
  • Edward W. Unkart, Member of Board of Directors

Last updated: 2024-12-31

Kiromic BioPharma, Inc.

Kiromic BioPharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

ALEXIS-ISO-1, ALEXIS-PRO-1

Kiromic Bio Pharma, Inc. is an artificial intelligence-driven allogeneic cell therapy company that develops multi-indication T cell therapies, leveraging the Gamma Delta T cell to target solid tumors. Key products include ALEXIS-ISO-1 and ALEXIS-PRO-1.

Tags: T cell therapies, artificial intelligence, biopharmaceutical, cell therapy, oncology

Symbol: KRBP

Recent Price: $0.93

Industry: Biotechnology

CEO: Mr. Pietro Bersani CPA, J.D.

Sector: Healthcare

Employees: 35

Address: 7707 Fannin, Houston, TX 77054

Phone: 832 968 4888

Leadership

  • Pietro Bersani, CPA, Director
  • Leonardo Mirandola, PhD, Chief Scientific Officer/Interim COO
  • Scott Dahlbeck, MD, PharmD, Chief of Staff
  • Brian Hungerford, Chief Financial Officer
  • Michael Nagel, Chairperson
  • Michael Catlin, Independent Director
  • Pam Misajon, Independent Director

Last updated: 2024-12-31

Aura Biosciences, Inc.

Aura Biosciences, Inc. logo
Market Cap: Medium
Employees: Low

AU-011

Aura Biosciences, Inc. operates as a biotechnology company developing virus-like drug conjugates (VDC) platform for treating ocular and urologic oncology tumors, with a focus on AU-011 for choroidal melanoma.

Tags: VDC technology, biotechnology, cancer therapy, choroidal melanoma, ocular oncology, oncology

Symbol: AURA

Recent Price: $8.13

Industry: Biotechnology

CEO: Dr. Elisabet de los Pinos Ph.D.

Sector: Healthcare

Employees: 88

Address: 85 Bolton Street, Cambridge, MA 02140

Phone: 617 500 8864

Leadership

  • David Johnson, Chairman
  • Elisabet de los Pinos, PhD, Chief Executive Officer
  • Giovanni Mariggi, PhD, Director
  • Antony Mattessich, Director
  • Sapna Srivastava, PhD, Director
  • Karan Takhar, Director

Last updated: 2024-12-31

Clearside Biomedical, Inc.

Clearside Biomedical, Inc. logo
Market Cap: Low
Employees: Lowest

XIPERE

Clearside Biomedical, Inc. is a biopharmaceutical company focused on revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. They offer treatments such as XIPERE for uveitis macular edema and are developing additional therapies for ocular conditions.

Tags: XIPERE, biopharmaceutical, clinical trials, macular edema, ocular therapies, suprachoroidal injection, uveitis

Symbol: CLSD

Recent Price: $0.99

Industry: Biotechnology

CEO: Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.

Sector: Healthcare

Employees: 30

Address: 900 North Point Parkway, Alpharetta, GA 30005

Phone: 678 270 3631

Last updated: 2024-12-31

Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Ik T-148009

Inhibikase Therapeutics, Inc. is a clinical stage pharmaceutical company focused on developing therapeutics for Parkinson's Disease and related disorders. Their product pipeline includes treatments for neurological and cancer-related conditions.

Tags: Cancer Treatment, Neurological Disorders, Parkinson's Disease, Pharmaceutical, Therapeutics

Symbol: IKT

Recent Price: $3.24

Industry: Biotechnology

CEO: Dr. Milton H. Werner Ph.D.

Sector: Healthcare

Employees: 8

Address: 3350 Riverwood Parkway SE, Atlanta, GA 30339

Phone: 678 392 3419

Leadership

  • Milton H. Werner, Ph.D., President and CEO
  • C. Warren Olanow MD, FRCPC, FRCP (Hon.), Medical Consultant and CEO of Clintrex Research Corporation
  • Garth Lees-Rolfe, CPA, Chief Financial Officer
  • Dan Williams, Controller
  • Terence Kelly, Ph.D., Medicinal Chemistry Consultant
  • Surendra Singh, Ph.D., Chemistry and Manufacturing Controls
  • Merrill M. Kraines, Partner, McDermott, Will & Emery, Outside General Counsel
  • Roberto Bellini, Managing Partner at BSQUARED Capital
  • Dennis Berman, Serial Entrepreneur
  • David Canner, Ph.D., Partner at Soleus Capital
  • Roy Freeman, M.D., Professor of Neurology at the Harvard Medical School, Director of the Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center
  • Arvind Kush, Chief Financial Officer and Chief Business Officer of Candid Therapeutics
  • Amit Munshi, Chief Executive Officer of Orna Therapeutics

Last updated: 2024-12-31

Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

KPI-012, EYSUVIS, INVELTYS

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for eye diseases using proprietary mucus penetrating particles technology.

Tags: biopharmaceutical, corneal epithelial defects, dry eye disease, eye diseases, gene expression, mucus penetrating particles, ocular surgery, retinal diseases

Symbol: KALA

Recent Price: $6.87

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Mark T. Iwicki

Sector: Healthcare

Employees: 43

Address: 1167 Massachusetts Avenue, Arlington, MA 02476

Phone: 781 996 5252

Last updated: 2024-12-31

Kodiak Sciences Inc.

Kodiak Sciences Inc. logo
Market Cap: Low
Employees: Low

KSI-301

Kodiak Sciences Inc., a clinical stage biopharmaceutical company based in Palo Alto, California, specializes in developing therapeutics for retinal diseases. Their lead product candidate, KSI-301, is a potential treatment for various retinal conditions and is currently in Phase IIb/III clinical trials.

Tags: biopharmaceutical, clinical trials, macular degeneration, retinal diseases, therapeutics

Symbol: KOD

Recent Price: $9.97

Industry: Biotechnology

CEO: Dr. Victor Perlroth M.D.

Sector: Healthcare

Employees: 111

Address: 1200 Page Mill Road, Palo Alto, CA 94304

Phone: 650 281 0850

Last updated: 2024-12-31

Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

KIO-301

Kiora Pharmaceuticals, Inc. develops therapies for ophthalmic diseases, with lead product KIO-301 in Phase 1 trial for vision restoration in degenerative retinal diseases and other products in trials for conditions like rheumatoid arthritis-related ocular issues and corneal wound repair.

Tags: clinical trials, ophthalmic diseases, ophthalmology, pharmaceuticals, vision restoration

Symbol: KPRX

Recent Price: $3.30

Industry: Biotechnology

CEO: Dr. Brian M. Strem Ph.D.

Sector: Healthcare

Employees: 12

Address: 1371 East 2100 South, Salt Lake City, UT 84105

Phone: 781 788 8869

Last updated: 2024-12-31

Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. logo
Market Cap: Low
Employees: Medium

XPOVIO

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing drugs targeting nuclear export for the treatment of cancer and other diseases, with a flagship product named XPOVIO.

Tags: SINE compounds, XPO1, cancer treatment, nuclear export, oncology, pharmaceutical

Symbol: KPTI

Recent Price: $0.70

Industry: Biotechnology

CEO: Mr. Richard A. Paulson M.B.A.

Sector: Healthcare

Employees: 325

Address: 85 Wells Avenue, Newton, MA 02459

Phone: 617 658 0600

Leadership

  • Richard Paulson, President and Chief Executive Officer
  • James Accumanno, Chief Compliance Officer
  • Brian Austad, Senior Vice President, Pharmaceutical Sciences
  • Sohanya Cheng, Chief Commercial Officer and Head of Business Development
  • Lisa DiPaolo, Chief Human Resources Officer
  • Mike Mano, Senior Vice President and General Counsel
  • Michael Mason, Chief Financial Officer
  • Stuart Poulton, Chief Development Officer
  • Reshma Rangwala, Chief Medical Officer & Head of Research
  • Amama Sadiq, Senior Vice President, Global Medical and Scientific Affairs
  • Elhan Webb, Senior Vice President, Investor Relations
  • Garen Bohlin, Director
  • Barry E. Greene, Lead Director
  • Mansoor Raza Mirza, MD, Director
  • Richard Paulson, MBA, President and Chief Executive Officer
  • Christy J. Oliger, Director
  • Deepa R. Pakianathan, PhD, Director
  • Chen Schor, Director
  • Zhen Su, MD, MBA, Director

Last updated: 2024-12-31

Keros Therapeutics, Inc.

Keros Therapeutics, Inc. logo
Market Cap: High
Employees: Low

KER-050

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for hematological and musculoskeletal disorders. Their lead product candidate, KER-050, targets cytopenias, including anemia and thrombocytopenia.

Tags: biopharmaceutical, clinical-stage, cytopenias, hematological disorders, musculoskeletal disorders

Symbol: KROS

Recent Price: $15.64

Industry: Biotechnology

CEO: Dr. Jasbir S. Seehra Ph.D.

Sector: Healthcare

Employees: 149

Address: 99 Hayden Avenue, Lexington, MA 02421

Phone: 617 314 6297

Leadership

  • Jasbir Seehra, Ph.D., Board Member
  • Keith Regnante, M.B.A., Chief Financial Officer
  • Christopher Rovaldi, President, Chief Operating Officer
  • Esther Cho, J.D., Senior Vice President, General Counsel
  • John Oram, M.B.A., Senior Vice President, Program and Portfolio Management
  • Robin Wagner, Senior Vice President, Human Resources
  • Carl L. Gordon, Ph.D., C.F.A., Board Member
  • Jean-Jacques BienaimΓ©, M.B.A., Lead Independent Director
  • Nima Farzan, M.B.A., Board Member
  • Mary Ann Gray, Ph.D., Board Member
  • Tomer Kariv, J.D., Board Member
  • Julius Knowles, M.B.A., Board Member
  • Ran Nussbaum, Board Member
  • Alpna Seth, Ph.D., Board Member

Last updated: 2024-12-31

Krystal Biotech, Inc.

Krystal Biotech, Inc. logo
Market Cap: High
Employees: Low

beremagene geperpavec (B-VEC)

Krystal Biotech, Inc., a clinical stage biotechnology company, focuses on redosable gene therapy for treating serious rare diseases in the United States, with a pipeline of products at various stages of development.

Tags: biotechnology, clinical stage, gene therapy, rare diseases, redosable gene therapy

Symbol: KRYS

Recent Price: $159.80

Industry: Biotechnology

CEO: Mr. Krish S. Krishnan M.B.A., M.S.

Sector: Healthcare

Employees: 229

Address: 2100 Wharton Street, Pittsburgh, PA 15203

Phone: 412 586 5830

Leadership

  • Krish Krishnan, Board Member
  • Suma Krishnan, Board Member
  • Kathryn Romano, EVP & Chief Accounting Officer
  • Laurent Goux, SVP & General Manager Europe
  • Jennifer McDonough, SVP, Patient Access, Analytics and Operations
  • Christine Wilson, Head of U.S. Sales and Marketing
  • Hiroshi Kasamoto, General Manager Japan
  • David Chien, SVP, Clinical Development
  • Ramesh Arjunji, SVP, Global Value and Access
  • John Thomas, General Counsel & Corporate Secretary
  • Trevor Parry, VP, Research and Scientific Affairs
  • StΓ©phane Paquette, VP, Business Development
  • Mark A. Petrich, VP, Process Development and Validation
  • Felino Obillo, VP, Global Supply Chain
  • Julian Gangolli, Board Member
  • Catherine Mazzacco, Board Member
  • Kirti Ganorkar, Board Member
  • Dino A. Rossi, Board Member
  • Dan Janney, Board Member
  • Chris Mason, Board Member
  • Rand Sutherland, Board Member

Last updated: 2024-12-31

Kura Oncology, Inc.

Kura Oncology, Inc. logo
Market Cap: High
Employees: Low

ziftomenib and tipifarnib

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company developing small molecule medicines for the treatment of cancer. It focuses on genetically defined subsets of acute leukemias and has a collaboration with Novartis for certain carcinoma treatments.

Tags: biopharmaceutical, cancer treatment, clinical trials, hematologic, leukemia, small molecule, solid tumors

Symbol: KURA

Recent Price: $8.51

Industry: Biotechnology

CEO: Dr. Troy Edward Wilson J.D., Ph.D.

Sector: Healthcare

Employees: 142

Address: 12730 High Bluff Drive, San Diego, CA 92130

Phone: 858 500 8800

Last updated: 2024-12-31

Kezar Life Sciences, Inc.

Kezar Life Sciences, Inc. logo
Market Cap: Lowest
Employees: Lowest

KZR-616

Kezar Life Sciences is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics to address unmet needs in immune-mediated diseases and cancer in the United States.

Tags: biotechnology, cancer, clinical trials, immune-mediated diseases, immunoproteasome inhibitor, small molecule therapeutics

Symbol: KZR

Recent Price: $6.82

Industry: Biotechnology

CEO: Dr. Christopher J. Kirk Ph.D.

Sector: Healthcare

Employees: 58

Address: 4000 Shoreline Court, South San Francisco, CA 94080

Phone: 650 822 5600

Leadership

  • Christopher Kirk, PhD, Chief Executive Officer, Co-Founder
  • Marc Belsky, Chief Financial Officer
  • Mark Schiller, Chief Legal Officer
  • Neel K. Anand, DPhil, SVP, Research and Drug Discovery
  • Zung To, SVP, Clinical Development
  • Gitanjali Jain, SVP, Investor Relations and External Affairs
  • Michelle Greenman, VP, Global Regulatory Affairs
  • Jim Kirchner, PhD, VP, CMC and Supply Chain
  • Andrew Basham, VP, Legal Affairs
  • Dave Braggs, VP, Quality Assurance
  • Pattie Chiang, SVP, Corporate Controller
  • Tony Muchamuel, VP, Pharmacology & Toxicology
  • Kiruthi Palaniswamy, PharmD, VP, Medical Affairs
  • Mary Rogers, VP, Financial Planning & Analysis
  • Joe Tedrick, VP, Human Resources
  • Jinhai Wang, PhD, VP, Drug Metabolism & Pharmacokinetics
  • John Fowler, Co-Founder
  • Graham Cooper, Board Member, Beam Therapeutics, Former CFO, Receptos
  • Franklin Berger, Founder
  • Elizabeth Garner, MD, MPH, Chief Science Officer
  • Michael Kauffman, MD, PhD, President, Chief Executive Officer, and Director
  • Micki Klearman, MD, Former Group Medical Director
  • Courtney Wallace, Venture Partner

Last updated: 2024-12-31

PDS Biotechnology Corporation

PDS Biotechnology Corporation logo
Market Cap: Low
Employees: Lowest

PDS0101

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing multifunctional cancer immunotherapies. Its lead product candidate, PDS0101, is in Phase II clinical trial for treating various human papillomavirus-associated malignancies.

Tags: biopharmaceutical, cancer immunotherapies, clinical trials, clinical-stage, oncology, vaccines

Symbol: PDSB

Recent Price: $1.69

Industry: Biotechnology

CEO: Dr. Frank K. Bedu-Addo Ph.D.

Sector: Healthcare

Employees: 25

Address: 25B Vreeland Road, Florham Park, NJ 07932

Phone: 800 208 3343

Leadership

  • Frank Bedu-Addo, Ph.D., Chief Executive Officer, Director
  • Stephan Toutain, Chief Operating Officer
  • Lars Boesgaard, Chief Financial Officer
  • Gregory Conn, Ph.D., Chief Scientific Officer
  • Kirk Shepard, M.D., Chief Medical Officer
  • Spencer Brown, Senior Vice-President, General Counsel, Corporate Secretary and Compliance Officer
  • Rory Cullinane, Vice President of Quality
  • Joe Dervan, Ph.D., Vice President of Research and Development
  • David Schaaf, M.D., Vice President of Medical Affairs
  • Sir Richard Sykes, Director
  • Ilian Iliev, Ph.D., Director
  • Gregory Freitag, J.D., CPA, Director
  • Otis W. Brawley, M.D., Director
  • Kamil Ali-Jackson, J.D., Director
  • Stephen Glover, Chairman

Last updated: 2024-12-31

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. logo
Market Cap: High
Employees: Medium

Crysvita, Mepsevii, Dojolvi, Evkeeza, DTX401, DTX301

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the development and commercialization of products for rare and ultra-rare genetic diseases worldwide.

Tags: Crysvita, Dojolvi, Evkeeza, Mepsevii, biopharmaceutical, gene therapy, genetic diseases, rare diseases

Symbol: RARE

Recent Price: $42.27

Industry: Biotechnology

CEO: Dr. Emil D. Kakkis M.D., Ph.D.

Sector: Healthcare

Employees: 1276

Address: 60 Leveroni Court, Novato, CA 94949

Phone: 415 483 8800

Last updated: 2024-12-31

Silo Pharma, Inc.

Silo Pharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

SPC-15

Silo Pharma Inc. is a developmental stage biopharmaceutical company focusing on treatments for stress-induced psychiatric disorders, chronic pain, and CNS diseases through traditional and psychedelic therapies.

Tags: CNS diseases, biopharmaceutical, chronic pain, psychedelic treatments, psychiatric disorders, traditional therapies

Symbol: SILO

Recent Price: $0.89

Industry: Biotechnology

CEO: Mr. Eric Weisblum

Sector: Healthcare

Employees: 3

Address: 677 N. Washington Boulevard, Sarasota, FL 34236

Phone: 718 400 9031

Last updated: 2024-12-31

Viking Therapeutics, Inc.

Viking Therapeutics, Inc. logo
Market Cap: Highest
Employees: Lowest

VK2809

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders, with lead drug candidate VK2809 in Phase IIb trials for non-alcoholic steatohepatitis.

Tags: VK2809, biopharmaceutical, clinical-stage, endocrine disorders, metabolic disorders, therapies

Symbol: VKTX

Recent Price: $39.77

Industry: Biotechnology

CEO: Dr. Brian Lian Ph.D.

Sector: Healthcare

Employees: 30

Address: 9920 Pacific Heights Boulevard, San Diego, CA 92121

Phone: 858 704 4660

Leadership

  • Lawson Macartney, DVM, Ph.D., Chairman
  • Matthew W. Foehr, Chief Executive Officer
  • Kathy Rouan, Ph.D.,
  • Charles A. Rowland Jr.,
  • Matthew Singleton,
  • Brian Lian, Ph.D.,

Last updated: 2024-12-31

Seelos Therapeutics, Inc.

Seelos Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

SLS-002, SLS-005, SLS-006, SLS-007, SLS-008, SLS-004, SLS-010

Seelos Therapeutics, Inc. is focused on developing and commercializing therapeutics for central nervous system, respiratory, and other disorders, with lead programs targeting major depressive disorders, amyotrophic lateral sclerosis, Sanfilippo syndrome, and Parkinson's disease.

Tags: ALS, Parkinson's disease, Sanfilippo syndrome, biopharmaceutical, central nervous system, major depressive disorder, respiratory disorders, therapeutics

Symbol: SEEL

Recent Price: $0.37

Industry: Biotechnology

CEO: Dr. Raj Mehra J.D., Ph.D.

Sector: Healthcare

Employees: 8

Address: 300 Park Avenue, New York, NY 10022

Phone: 646 293 2100

Last updated: 2024-12-31

Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

STK-001, STK-002

Stoke Therapeutics, Inc. is an early-stage biopharmaceutical company focused on developing antisense oligonucleotide medicines to treat genetic diseases. Their lead product, STK-001, is aimed at treating Dravet syndrome, while STK-002 targets autosomal dominant optic atrophy.

Tags: Dravet syndrome, antisense oligonucleotides, biopharmaceutical, epilepsy, genetic diseases, genetic medicine

Symbol: STOK

Recent Price: $10.80

Industry: Biotechnology

CEO: Dr. Edward M. Kaye M.D., Ph.D.

Sector: Healthcare

Employees: 110

Address: 45 Wiggins Avenue, Bedford, MA 01730

Phone: 781 430 8200

Leadership

  • Edward M. Kaye, M.D., Chief Executive Officer & Director
  • Jonathan Allan, J.D., General Counsel
  • Isabel Aznarez, Ph.D., Senior Vice President, Discovery Research and Co-Founder
  • Jason Hoitt, Chief Commercial Officer
  • Dawn Kalmar, Chief Communications Officer
  • Tommy Leggett, Chief Financial Officer
  • Shamim Ruff, Chief Regulatory Officer
  • Barry S. Ticho, M.D., Ph.D., FACC, Chief Medical Officer
  • Joan Wood, Chief Human Resources Officer
  • Adrian Krainer, Ph.D., Co-founder & Director
  • Arthur Tzianabos, Ph.D., Chairman
  • Jennifer Burstein, MBA, CPA, Director
  • Seth L. Harrison, M.D., Director
  • Arthur Levin, Ph.D., Director
  • Garry E. Menzel, Ph.D., MBA, Director
  • Ian F. Smith, Director
  • Julie Anne Smith, Director

Last updated: 2024-12-31

Kodiak Gas Services, Inc.

Kodiak Gas Services, Inc. logo
Market Cap: High
Employees: Medium

Contract Compression Infrastructure

Kodiak Gas Services, Inc. operates contract compression infrastructure for customers in the oil and gas industry in the United States, providing both Compression Operations and Other Services.

Tags: Ancillary Compression, CAREERS, Contract Compression, Contract Services, Enhanced Oil Recovery, Gas Gathering, Gas Processing, Midstream Infrastructure, Multi Well Gas Lift Systems, Production Infrastructure

Symbol: KGS

Recent Price: $40.92

Industry: Oil & Gas Equipment & Services

CEO: Mr. Robert M. McKee

Sector: Energy

Employees: 781

Address: 15320 Highway 105 West, Montgomery, TX 77356

Phone: 936-539-3300

Last updated: 2024-12-31